Pfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents (updated)

CureVac NV

08/10/2024 10:55

(Adds details)
       LONDON, Oct 8 (Reuters) - Pfizer  PFE.N  and its German
partner BioNTech  22UAy.DE  on Tuesday won their attempt to
invalidate two of rival CureVac's  5CV.DE  patents at London's
High Court.
    Pfizer and BioNTech had filed their lawsuit in September
2022 over patents relating to messenger RNA (mRNA) technology,
which underpins Pfizer and BioNTech's COVID-19 vaccine.
    Tuesday's ruling relates to the London leg of Pfizer,
BioNTech and CureVac's global legal battle, which also involves
litigation in the United States and Germany.
        Pfizer and BioNTech are separately involved in a case
with Moderna  MRNA.O  over their rival COVID-19 vaccines.
  
        The High Court 
    ruled
     in that case in July that one of Moderna's mRNA patents was
valid and Pfizer and BioNTech's Comirnaty vaccine had infringed
it. Pfizer and BioNTech have been 
    granted
     permission to appeal against that decision.
  

 (Reporting by Sam Tobin; Editing by Sachin Ravikumar and Sarah
Young)
 ((Sam.Tobin@thomsonreuters.com;))